Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.

Boris A Margulis, Vladimir Vigont, Vladimir F Lazarev, Elena V Kaznacheyeva, Irina V Guzhova

Institute of Cytology of Russian Academy of Sciences, Tikhoretsky pr., 4, St. Petersburg 194064, Russia.

FEBS letters 2013 Jun 27

filter terms:

Polyglutamine diseases are a group of pathologies affecting different parts of the brain and causing dysfunction and atrophy of certain neural cell populations. These diseases stem from mutations in various cellular genes that result in the synthesis of proteins with extended polyglutamine tracts. In particular, this concerns huntingtin, ataxins, and androgen receptor. These mutant proteins can form oligomers, aggregates, and, finally, aggresomes with distinct functions and different degrees of cytotoxicity. In this review, we analyze the effects of different forms of polyQ proteins on other proteins and their functions, which are considered as targets for therapeutic intervention. Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Citation

Boris A Margulis, Vladimir Vigont, Vladimir F Lazarev, Elena V Kaznacheyeva, Irina V Guzhova. Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors. FEBS letters. 2013 Jun 27;587(13):1997-2007